氰基甲酮 | 4248-66-2

• 分子结构分类: 有机化合物 - 脂质和类脂质分子 - 类固醇和类固醇衍生物
• 中文名称: 氰基甲酮
• 中文别名: 5-[1-羟基-2-(2,4,5-三氟苯基)亚乙基]-2,2-二甲基-1,3-二噁烷-4,6-二酮
• 英文名称: 2α-cyano-17β-hydroxy-4,4,17α-trimethylandrost-5-en-3-one
• 英文别名: 17β-hydroxy-4,4,17-trimethyl-3-oxoandrost-5-ene-2α-carbonitrile；2α-cyano-4,4,17α-trimethyl-17β-hydroxy-5-androsten-3-one；cyano-ketone；cyanoketone；cyanotrimethylandrostenolone；4,4,17α-Trimethyl-2α-cyan-androsten-(5)-ol-(17β)-on-(3)；(2S,8R,9S,10R,13S,14S,17S)-17-hydroxy-4,4,10,13,17-pentamethyl-3-oxo-1,2,7,8,9,11,12,14,15,16-decahydrocyclopenta[a]phenanthrene-2-carbonitrile
• CAS: 4248-66-2
• 化学式: C₂₃H₃₃NO₂
• 分子量: 355.521
• InChiKey: GTBRTGPZZALPNS-MXHVRSFHSA-N

物化性质

• 沸点：
  488.52°C (rough estimate)
• 密度：
  1.0534 (rough estimate)

计算性质

• 辛醇/水分配系数(LogP)：
  4.1
• 重原子数：
  26
• 可旋转键数：
  0
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.83
• 拓扑面积：
  61.1
• 氢给体数：
  1
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  2-cyano-4,4,17α-trimethylandrosta-2,5-diene-3,17β-diol 、 三甲基乙酰氯 、 氰基甲酮 以 吡啶 为溶剂， 生成 3-(trimethylacetyloxy)-17β-hydroxy-4,4,17α-trimethylandrosta-2,5-diene-2-carbonitrile
  参考文献：
  名称：

  Method for the induction of menses

  摘要：

  本发明涉及一种通过给予IV式化合物的方法来诱导月经或终止妊娠的方法。

  公开号：

  US04388311A1
• 作为产物：
  描述：

  阿查斯顿 在 sodium methylate 作用下， 以 四氢呋喃 为溶剂， 生成 氰基甲酮
  参考文献：
  名称：

  甾体杂环。七。雄甾烷（2,3-D）异恶唑及相关化合物。

  摘要：

  DOI：

  10.1021/jm00337a001
• 作为试剂：
  描述：

  胆固醇 在 氰基甲酮 、 还原型辅酶II(NADPH)四钠盐 、 magnesium chloride 、 Tween 20 作用下， 反应 0.5h， 生成 孕烯醇酮
  参考文献：
  名称：

  Cholesterol side-chain cleavage activity in human placenta and bovine adrenals: An one-step method for separation of pregnenolone formed in vitro

  摘要：

  Cholesterol side-chain cleavage (CSCC) activity towards exogenous cholesterol was quantified by an one-step reversed-phase minicolumn method for the separation of pregnenolone formed in the reaction. The assay is rapid and reproducible. The method is linear for up to 2 mg of placental mitochondrial protein and up to 1 mg of bovine adrenal mitochondrial protein in the incubata over 30 min and 5 min reaction times, respectively. Average Km and Vmax values were 14.1 microM and 3.4 pmol/min/mg for the placental preparation and 1.5 microM and 20.7 pmol/min/mg for the bovine adrenal mitochondrial preparation. In human placenta, the mitochondrial fraction contained most of the CSCC activity. Inhibition studies showed that aminoglutethimide (500 microM) inhibited both placental and bovine adrenal activities at the same level (about 80-90% inhibition) but androstenedione (500 microM), metyrapone (500 microM), benzo(a)pyrene (800 microM) and Emulgen 911 (0.05%) were more effective in human placental preparations. Neither of the activities were inhibited to any great extent by alpha-naphthoflavone (500 microM), SKF 525A (500 microM) or 7-ethoxycoumarin (1 mM).

  DOI：

  10.1016/s0039-128x(84)90156-9

文献信息

• [EN] BICYCLIC HETEROARYL UREA, THIOUREA, GUANIDINE AND CYANOGUANIDINE COMPOUNDS AS TRKA KINASE INHIBITORS<br/>[FR] COMPOSÉS D'HÉTÉROARYLE URÉE, THIOURÉE,GUANIDINE ET CYANOGUANIDINE EN TANT QU'INHIBITEURS DE LA KINASE TRKA
  申请人：ARRAY BIOPHARMA INC

  公开号：WO2014078408A1

  公开（公告）日：2014-05-22

  Compounds of Formula I or stereoisomers, tautomers, or pharmaceutically acceptable salts, solvates or prodrugs thereof, wherein Ring A, Ring C and X are as defined herein, are inhibitors of TrkA kinase and are useful in the treatment of diseases which can be treated with a TrkA kinase inhibitor such as pain, cancer, inflammation/inflammatory diseases, neurodegenerative diseases, certain infectious diseases, Sjogren's syndrome, endometriosis, diabetic peripheral neuropathy, prostatitis and pelvic pain syndrome.

  式I化合物或其立体异构体、互变异构体或药学上可接受的盐、溶剂合物或前药，其中环A、环C和X如本文所定义，是TrkA激酶的抑制剂，并且在治疗可以用TrkA激酶抑制剂治疗的疾病中具有用处，如疼痛、癌症、炎症/炎症性疾病、神经退行性疾病、某些传染病、干燥综合征、子宫内膜异位症、糖尿病周围神经病变、前列腺炎和盆腔疼痛综合征。
• [EN] N-(ARYLALKYL)-N'-PYRAZOLYL-UREA, THIOUREA, GUANIDINE AND CYANOGUANIDINE COMPOUNDS AS TRKA KINASE INHIBITORS<br/>[FR] COMPOSÉS DE N-(ARYLALKYLE)-N'-PYRAZOLYLE-URÉE, DE THIOURÉE, DE GUANIDINE ET DE CYANOGUANIDINE EN TANT QU'INHIBITEURS DE LA KINASE TRKA
  申请人：ARRAY BIOPHARMA INC

  公开号：WO2014078331A1

  公开（公告）日：2014-05-22

  Compounds of Formula I or stereoisomers, tautomers, or pharmaceutically acceptable salts, solvates or prodrugs thereof, wherein Ring A, Ring C, X, Ra, Rb, Rc, Rd and n are as defined herein, are inhibitors of TrkA kinase and are useful in the treatment of diseases which can be treated with a TrkA kinase inhibitor such as pain, cancer, inflammation/inflammatory diseases, neurodegenerative diseases, certain infectious diseases, Sjogren's syndrome, endometriosis, diabetic peripheral neuropathy, prostatitis or pelvic pain syndrome.

  公式I的化合物或立体异构体、互变异构体、或药用可接受的盐、溶剂化物或前药，其中环A、环C、X、Ra、Rb、Rc、Rd和n如本文所述定义，是TrkA激酶的抑制剂，可用于治疗可以用TrkA激酶抑制剂治疗的疾病，如疼痛、癌症、炎症/炎症性疾病、神经退行性疾病、某些传染病、舍格伦综合症、子宫内膜异位症、糖尿病周围神经病变、前列腺炎或骨盆疼痛综合征。
• [EN] BICYCLIC UREA, THIOUREA, GUANIDINE AND CYANOGUANIDINE COMPOUNDS USEFUL FOR THE TREATMENT OF PAIN<br/>[FR] COMPOSÉS DE THIO-URÉE, GUANIDINE, CYNOGUANIDINE ET D'URÉE BICYCLIQUES UTILES POUR LE TRAITEMENT DE LA DOULEUR
  申请人：ARRAY BIOPHARMA INC

  公开号：WO2014078454A1

  公开（公告）日：2014-05-22

  Compounds of Formula I: or stereoisomers, tautomers, or pharmaceutically acceptable salts, solvates or prodrugs thereof, wherein Ring A, Ring C and X are as defined herein, are inhibitors of TrkA kinase and are useful in the treatment of diseases which can be treated with a TrkA kinase inhibitor such as pain, cancer, inflammation/inflammatory diseases, neurodegenerative diseases, certain infectious diseases, Sjogren's syndrome, endometriosis, diabetic peripheral neuropathy, prostatitis and pelvic pain syndrome.

  公式I的化合物：或立体异构体、互变异构体、或药用可接受的盐、溶剂化物或前药，其中环A、环C和X如本文定义，是TrkA激酶的抑制剂，可用于治疗可以用TrkA激酶抑制剂治疗的疾病，如疼痛、癌症、炎症/炎症性疾病、神经退行性疾病、某些传染病、舍格伦综合症、子宫内膜异位症、糖尿病周围神经病、前列腺炎和盆腔疼痛综合症。
• Sulfonate Catalyst and Method of Producing Alcohol Compound Using the Same
  申请人：Utsumi Noriyuki

  公开号：US20080234525A1

  公开（公告）日：2008-09-25

  A sulfonate catalyst represented by the formula below and a ketone compound are placed in a solvent, and the ketone compound is hydrogenated by mixing in the presence of hydrogen to produce an optically active alcohol.

  使用下面公式表示的磺酸盐催化剂和酮类化合物放入溶剂中，然后在氢气存在下进行混合，将酮类化合物氢化，产生具有光学活性的醇。
• [EN] NOVEL PYRAZOLO[1,5-a]PYRROLO[3,2-e]PYRIMIDINE DERIVATIVES AS mTOR INHIBITORS<br/>[FR] NOUVEAUX DÉRIVÉS DE PYRAZOLO[1,5-A]PYRROLO[3,2-E]PYRIMIDINE UTILISÉS COMME INHBITEURS DE MTOR
  申请人：SCHERING CORP

  公开号：WO2012027239A1

  公开（公告）日：2012-03-01

  The present invention relates to certain pyrazolo[1,5-a]pyrrolo[3,2-e]pyrimidine compounds of Formula (I) as inhibitors of mammalian Target of Rapamycin (mTOR) kinase, which is also known as FRAP, RAFT, RAPT or SEP. The compounds may be used in the treatment of cancer and other disorders where mTOR is deregulated. The present invention further provides pharmaceutical compositions comprising the pyrazolo[1,5-a]pyrrolo[3,2-e]pyrimidine compounds.

  本发明涉及某些吡唑[1,5-a]吡咯[3,2-e]嘧啶化合物，其化学式为(I)，作为哺乳动物雷帕霉素靶点(mTOR)激酶的抑制剂，也被称为FRAP、RAFT、RAPT或SEP。这些化合物可用于治疗癌症和其他mTOR失调的疾病。本发明进一步提供了包含吡唑[1,5-a]吡咯[3,2-e]嘧啶化合物的药物组合物。